[go: up one dir, main page]

BRPI0419117A - ácido nucléico isolado, vetor, célula hospedeira, processo para produção, polipeptìdeo isolado, molécula quimérica, anticorpo, anticorpo isolado, composição de interesse, artigo de fabricação, método de alìvio de uma disfunção imune relacionada, método para determinar a presença de um polipeptìdeo em uma amostra suspeita de conter dito polipeptìdeo, método de diagnóstico de uma doença imune relacionada em um mamìfero, método de alìvio de linfoma em um mamìfero em necessidade deste, método de alìvio de doença inflamatória de intestino em um mamìfero em necessidade deste e método de alìvio de rejeição de células transplantadas em um mamìfero - Google Patents

ácido nucléico isolado, vetor, célula hospedeira, processo para produção, polipeptìdeo isolado, molécula quimérica, anticorpo, anticorpo isolado, composição de interesse, artigo de fabricação, método de alìvio de uma disfunção imune relacionada, método para determinar a presença de um polipeptìdeo em uma amostra suspeita de conter dito polipeptìdeo, método de diagnóstico de uma doença imune relacionada em um mamìfero, método de alìvio de linfoma em um mamìfero em necessidade deste, método de alìvio de doença inflamatória de intestino em um mamìfero em necessidade deste e método de alìvio de rejeição de células transplantadas em um mamìfero

Info

Publication number
BRPI0419117A
BRPI0419117A BRPI0419117-0A BRPI0419117A BRPI0419117A BR PI0419117 A BRPI0419117 A BR PI0419117A BR PI0419117 A BRPI0419117 A BR PI0419117A BR PI0419117 A BRPI0419117 A BR PI0419117A
Authority
BR
Brazil
Prior art keywords
mammal
polypeptide
relief
isolated
need
Prior art date
Application number
BRPI0419117-0A
Other languages
English (en)
Inventor
Hilary Clark
Daniel L Eaton
Bernd Wranik
Wenjun Ouyang
Lino Gonzalez
Kelly M Loyet
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0419117A publication Critical patent/BRPI0419117A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)

Abstract

áCIDO NUCLéICO ISOLADO, VETOR, CéLULA HOSPEDEIRA, PROCESSO PARA PRODUçãO, POLIPEPTìDEO ISOLADO, MOLéCULA QUIMéRICA, ANTICORPO, ANTICORPO ISOLADO, COMPOSIçãO DE INTERESSE, ARTIGO DE FABRICAçãO, MéTODO DE ALìVIO DE UMA DISFUNçãO IMUNE RELACIONADA, MéTODO PARA DETERMINAR A PRESENçA DE UM POLIPEPTìDEO EM UMA AMOSTRA SUSPEITA DE CONTER DITO POLIPEPTìDEO, MéTODO DE DIAGNóSTICO DE UMA DOENçA IMUNE RELACIONADA EM UM MAMìFERO, MéTODO DE ALìVIO DE LINFOMA EM UM MAMìFERO EM NECESSIDADE DESTE, MéTODO DE ALìVIO DE DOENçA INFLAMATóRIA DE INTESTINO EM UM MAMìFERO EM NECESSIDADE DESTE E MéTODO DE ALìVIO DE REJEIçãO DE CéLULAS TRANSPLANTADAS EM UM MAMìFERO A presente invenção refere-se a composições que contém nova proteína e métodos de uso dessas composições para o diagnóstico e tratamento de doença imune relacionada.
BRPI0419117-0A 2004-11-12 2004-11-12 ácido nucléico isolado, vetor, célula hospedeira, processo para produção, polipeptìdeo isolado, molécula quimérica, anticorpo, anticorpo isolado, composição de interesse, artigo de fabricação, método de alìvio de uma disfunção imune relacionada, método para determinar a presença de um polipeptìdeo em uma amostra suspeita de conter dito polipeptìdeo, método de diagnóstico de uma doença imune relacionada em um mamìfero, método de alìvio de linfoma em um mamìfero em necessidade deste, método de alìvio de doença inflamatória de intestino em um mamìfero em necessidade deste e método de alìvio de rejeição de células transplantadas em um mamìfero BRPI0419117A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/037612 WO2006054961A2 (en) 2004-11-12 2004-11-12 Novel composition and methods for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
BRPI0419117A true BRPI0419117A (pt) 2007-12-11

Family

ID=34959520

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0419117-0A BRPI0419117A (pt) 2004-11-12 2004-11-12 ácido nucléico isolado, vetor, célula hospedeira, processo para produção, polipeptìdeo isolado, molécula quimérica, anticorpo, anticorpo isolado, composição de interesse, artigo de fabricação, método de alìvio de uma disfunção imune relacionada, método para determinar a presença de um polipeptìdeo em uma amostra suspeita de conter dito polipeptìdeo, método de diagnóstico de uma doença imune relacionada em um mamìfero, método de alìvio de linfoma em um mamìfero em necessidade deste, método de alìvio de doença inflamatória de intestino em um mamìfero em necessidade deste e método de alìvio de rejeição de células transplantadas em um mamìfero

Country Status (11)

Country Link
EP (1) EP1812465B1 (pt)
JP (1) JP4901747B2 (pt)
KR (1) KR101224659B1 (pt)
CN (1) CN101421298A (pt)
AU (1) AU2004325035B2 (pt)
BR (1) BRPI0419117A (pt)
CA (1) CA2586615C (pt)
ES (1) ES2602731T3 (pt)
IL (2) IL182643A (pt)
MX (1) MX2007005612A (pt)
WO (1) WO2006054961A2 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188232B1 (en) 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175855A1 (en) * 2002-10-25 2009-07-09 Hilary Clark Novel compositions and methods for the treatment of immune related diseases
CA2503125C (en) 2002-10-25 2013-04-30 Hilary Clark Novel composition and methods for the treatment of immune related diseases
US8349320B2 (en) 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
EA200970477A1 (ru) 2006-11-15 2009-12-30 Медарекс, Инк. Человеческие моноклональные антитела к btla и способы применения
WO2009039310A2 (en) * 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
US20100203047A1 (en) * 2007-10-05 2010-08-12 University Of Maryland, Baltimore Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
JP5660027B2 (ja) * 2009-03-05 2015-01-28 味の素株式会社 クローン病診断試薬
IN2012DN00863A (pt) * 2009-07-31 2015-07-10 Medarex Inc
US9056910B2 (en) * 2012-05-01 2015-06-16 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
KR102669985B1 (ko) * 2015-06-30 2024-05-29 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 Btla 융합 단백질 작용제 및 이의 용도
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
JP7582940B2 (ja) 2018-10-31 2024-11-13 ジュノ セラピューティクス ゲーエムベーハー 細胞の選択および刺激のための方法ならびにそのための装置
EP3877054B1 (en) 2018-11-06 2023-11-01 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
CN114929360A (zh) 2019-10-30 2022-08-19 朱诺治疗学有限公司 细胞选择和/或刺激装置及使用方法
JP2023526278A (ja) 2020-05-13 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
WO2021250323A1 (en) * 2020-06-09 2021-12-16 Helsingin Yliopisto Anti-cox-2 autoantibody as a diagnostic marker, and methods, kits and uses related thereto
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440618A1 (en) * 2001-03-12 2002-09-19 Incyte Genomics, Inc. Immunoglobulin superfamily proteins
CA2503125C (en) * 2002-10-25 2013-04-30 Hilary Clark Novel composition and methods for the treatment of immune related diseases
EP1633784B1 (en) * 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
US9045562B2 (en) 2002-06-20 2015-06-02 Washington University Compositions and methods for modulating lymphocyte activity
US8188232B1 (en) 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
US8303952B2 (en) 2009-06-08 2012-11-06 Washington University Methods for inducing in vivo tolerance
US8642033B2 (en) 2009-06-08 2014-02-04 Washington University Methods for inducing in vivo tolerance

Also Published As

Publication number Publication date
MX2007005612A (es) 2007-08-14
EP1812465B1 (en) 2016-09-07
JP4901747B2 (ja) 2012-03-21
CA2586615A1 (en) 2006-05-26
JP2008519599A (ja) 2008-06-12
AU2004325035A2 (en) 2006-05-26
AU2004325035B2 (en) 2011-09-08
KR101224659B1 (ko) 2013-01-21
IL182643A0 (en) 2007-07-24
EP1812465A1 (en) 2007-08-01
CA2586615C (en) 2017-06-27
CN101421298A (zh) 2009-04-29
IL228819A0 (en) 2013-12-31
ES2602731T3 (es) 2017-02-22
KR20070086020A (ko) 2007-08-27
IL182643A (en) 2013-11-28
WO2006054961A2 (en) 2006-05-26
AU2004325035A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
BRPI0419117A (pt) ácido nucléico isolado, vetor, célula hospedeira, processo para produção, polipeptìdeo isolado, molécula quimérica, anticorpo, anticorpo isolado, composição de interesse, artigo de fabricação, método de alìvio de uma disfunção imune relacionada, método para determinar a presença de um polipeptìdeo em uma amostra suspeita de conter dito polipeptìdeo, método de diagnóstico de uma doença imune relacionada em um mamìfero, método de alìvio de linfoma em um mamìfero em necessidade deste, método de alìvio de doença inflamatória de intestino em um mamìfero em necessidade deste e método de alìvio de rejeição de células transplantadas em um mamìfero
Schweitzer et al. Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis
Duong et al. Proteomics in forensic analysis: Applications for human samples
Burger et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies
Guerrier et al. Exploring the platelet proteome via combinatorial, hexapeptide ligand libraries
Peng et al. Proteomic analysis of symbiosome membranes in Cnidaria–dinoflagellate endosymbiosis
EP3455371B1 (en) Tissue-specific exosomes as biomarkers
Gannon et al. Drastic increase of myosin light chain MLC-2 in senescent skeletal muscle indicates fast-to-slow fibre transition in sarcopenia of old age
Heiri et al. Stable isotopic analysis of fossil chironomids as an approach to environmental reconstruction: state of development and future challenges
Bonicelli et al. Insights into the differential preservation of bone proteomes in inhumed and entombed cadavers from Italian forensic caseworks
Gu et al. Fab fragment glycosylated IgG may play a central role in placental immune evasion
BRPI0509419A (pt) método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
WO2015168602A2 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
Ruperti et al. Molecular profiling of sponge deflation reveals an ancient relaxant-inflammatory response
MX2025004565A (es) Anticuerpos anti-cd3 dependientes de ph y metodos relacionados con estos
BRPI0712273A8 (pt) anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
JP2020502498A (ja) ヒトの皮膚の老化の新規バイオマーカー
Li et al. Programmed DNA tile response system enabled accurate detection of ATP for clinical diagnosis
RU2009144277A (ru) Способы и композиции для диагностики остеоартрита у животного семейства кошачьих
Moreno et al. Monitoring Autophagy in Human Aging: Key Cell Models and Insights
EP2746768A1 (en) Podxl in bladder cancer
McKiernan et al. NextGen serology: leveraging mass spectrometry for protein-based human body fluid identification
BRPI0606307A2 (pt) formas de fator xlla e métodos para determinar as referidas formas
ATE500275T1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
Zhang et al. Serum proteomic analysis of differentially expressed proteins and pathways involved in the mechanism of endemic osteoarthritis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.